IMPORTANT MESSAGE
Like many other companies and institutions around the world, we are experiencing interference with some of our systems within the TNT network.
We are implementing remediation steps as quickly as possible. We have implemented operational contingencies to continue to complete collections from customers with scheduled stops. For customers who do not have a regular stop, collection should be arranged via our customer service centers.
Customers may experience delays in the transit of shipments, particularly inter-continental or non-EU European delivery, as we work to remediate our systems. Additionally, if customers do not have the facility for self-labeling, they may also experience delays.
We are not able to collect shipments of dangerous goods at this time.
We regret any inconvenience to our customers.
Supplying Costly Investigational Product: Pre-Randomisation Approach Reduces Drug Wastage
Supplying Costly Investigational Product: Pre-Randomisation Approach Reduces Drug Wastage
Certainly, every sponsor wants to minimize wastage in clinical trial supplies, but the motivation to do so is extraordinary when the product under study is unusually expensive. A top-tier, international pharmaceutical company engaged Almac to ensure that it did not incur undue drug supply costs for a global study involving a very expensive investigational product. With some ingenuity and customisations to the IXRS® platform for managing patients, supplies, and trial data,
Almac helped the client re-envision its study design and supply strategy.
